GEN Exclusives

More »

GEN News Highlights

More »
Jan 16, 2007

Pfizer Attains Rights to Genizon BioSciences Discovery Programs

  • Genizon BioSciences reported a license and collaboration agreement with Pfizer for diagnostic rights to Genizon’s discovery programs in Alzheimer’s disease, attention deficit hyperactivity disorder, and endometriosis. Genizon retains therapeutic rights.

    Under the terms of the agreement, Pfizer will pay Genizon upfront license fees and funding for research on genetic variations associated with the diseases. Pfizer will also purchase an equity stake in Genizon.

    The collaboration involves discovery of diagnostic markers from three ongoing genome-wide association studies of the Quebec Founder Population using Genizon’s technology platform. The unique genetic heritage of the Quebec Founder Population facilitates discovery of genetic markers that are predictive of disease susceptibility, according to the company.
    The collaboration will expand these discoveries by including results with those from genome wide association studies from general populations.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Children and Antipsychotic Drugs

Do you think children and adolescents with behavioral problems are overmedicated?